

Performance In Delivering - Q2: 2018/2019 (1st October 2017 - 30th September 2018)

| Research Ethics Committee Reference Number | IRAS number | Name of Trial | Target number of patients agreed? | Target minimum number of patients | Target maximum number of patients | Target date to recruit patients agreed? | Date Agreed to recruit target number of patients | Number of patients recruited by agreed date | Total number of study participants recruited | Closed to Recruitment date | Reason for Closure |
|--|-------------|---|-----------------------------------|-----------------------------------|-----------------------------------|---|--|---|--|----------------------------|---|
| 15/EM/0552 | 189887 | CIRCLE: A randomised, sham-controlled, double-masked, multi-centre study to evaluate the effect of ocriplasmin 0.125mg in subjects with non-proliferative diabetic retinopathy (NPDR) | Agreed | 3 | 3 | Agreed | 31/07/2017 | 1 | 3 | 07/12/2017 | End of Recruitment |
| 16/LO/2128 | 216431 | PANORAMA: Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) | Agreed | 22 | 22 | Agreed | 28/02/2019 | 9 | 9 | 09/11/2017 | End of Recruitment - study closed early |